SecBot SecBot
424B5 ·Filed Apr 15, 2026

RVMDW

Revolution Medicines, Inc.
NEUTRAL
Impact 6/10
Horizondays Processed7mo ago SEC0001193125-26-157273
Notable filing: 424B5
Actionable Insight • Neutral

Monitor whether the concurrent convertible note offering closes, as this could add significant future dilution. The substantial dilution for new investors suggests caution, though the capital infusion strengthens the company's R&D runway.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.88
T+0 close · Apr 15, 2026 · via day close
Latest settled
+376.60%
T+60 · $8.96
Vs SPY
+369.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 16 $1.88entry
  2. T+1 · 7mo ago 0.00%α −1.21% · $1.88
  3. T+5 · 7mo ago 0.00%α −0.98% · $1.88
  4. T+20 · 6mo ago 0.00%α −5.82% · $1.88
  5. T+60 · 4mo ago +376.60%α +369.55% · $8.96
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines is raising $1.44 billion through a public offering of 10.56 million common shares at $142.00 per share, alongside a concurrent $500 million convertible note offering. The proceeds will fund R&D and general corporate purposes.

Key Facts

  • Offering 10,563,381 shares of common stock at $142.00 per share, raising $1.44 billion in gross proceeds
  • Concurrent offering of $500 million in 0.50% convertible senior notes due 2033
  • Net proceeds estimated at $1.435 billion after underwriting discounts and expenses
  • Proceeds to be used for R&D, potential commercialization, general corporate purposes, and possible acquisitions
  • Significant dilution for new investors: $127.57 per share based on $7.92 book value vs. $142.00 offering price

Financial Impact

$1.44 billion raised from equity offering and $500 million from convertible notes

cashdilutiondebt

Risk Factors

  • Immediate and substantial dilution for new investors
  • Potential for additional dilution from the concurrent $500 million convertible note offering
  • Future sales from the $1 billion ATM program could pressure stock price

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-157273
Document: d93698dexfilingfees.htm0001193125-26-157273
Document: 0001193125-26-157273-index-headers.html0001193125-26-157273
Document: 0001193125-26-157273-index.html0001193125-26-157273
Document: 0001193125-26-157273.txt0001193125-26-157273

Track record

8 reports on RVMDW

Performance horizon

0 of 3 bullish or bearish reports moved the stock their way by T+60. Best: 0.00% at T+1 after the Apr 15, 2026 report. 0 of 3 went positive at some point.

Filters
  1. Apr 17, 202630w ago 8-K Bearish 8/10 Entry $1.88 to $9.07 ▼ −382.45% −375.67% vs SPY
  2. Apr 16, 202630w ago 8-K Neutral 6/10 Entry $1.88 to $8.98 ▲ +377.66% +371.52% vs SPY
  3. Apr 15, 202630w ago 424B5 Neutral 6/10 Viewing Entry $1.88 to $8.96 ▲ +376.60% +369.55% vs SPY
  4. Apr 15, 202630w ago 424B5 Bearish 7/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
  5. Apr 15, 202630w ago 144 Bearish 6/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
  6. Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
  7. Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
  8. Apr 13, 202631w ago 8-K Bullish 8/10 Entry $1.88 No price data
Showing 8 of 8

US Market Status

Market Closed · Opens in 7h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026